USPTO serial 98384819
IGI
Reviewed by CopyMark Law Group
Status 732Notice of Allowance
- Filing date
- Status date
- Registration date
- —
- Examiner
- MCBRIDE, THEODORE M
- Law office
- INTENT TO USE SECTION
What this means
The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.
Need help with IGI?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,545*
Plus Government fees of $750
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maxim A. Voltchenko
Maxim A. Voltchenko Kaplan Breyer Schwarz, LLP317 George Street, Ste 320South WingNew Brunswick, NJ 08901Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 003 | Skin soaps; shampoos; sunscreen for cosmetic use; perfumery; essential oils; body powder; cosmetics; anti-aging creams; hair lotion; skin creams; skin moisturizing gels; non-medicated soaps for face; moisturizing body lotions; non-medicated mouthwashes | ACTIVE | — |
| 005 | Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma | ACTIVE | — |
| 010 | Spirometer; inhalers for therapeutic use, sold empty; chambers for inhalers; nebulizers for medical purposes; diagnostic apparatus for medical purposes, namely, medical diagnostic apparatus for testing DNA and RNA samples | ACTIVE | — |
| 042 | Scientific research for medical purposes; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific and technological services, namely, scientific research, analysis, testing in the field of oncology, immunology and pain management; medical research in the fields of oncology, immunology and pain management; clinical research in the fields of oncology, immunology and pain management; scientific research and development; pharmaceutical drug development services; pharmaceutical research and development; research and development for new products for others; scientific and technological services, namely, scientific research and analysis in the field of chemicals, pharmaceutical preparations, dietetic preparations, demo-cosmetic preparations, and biotechnology; design and testing for new product development; medical research; scientific research in the fields of chemistry, biotechnology and pharmacology; medical and pharmaceutical research services; scientific research services for medical purposes, namely, bacteriological research services; biomedical research services; laboratory research services in the field of cancer treatment, oncology, immunology and pain management; medical and scientific research, namely, conducting clinical trials for others; scientific research in the field of pharmacology; medical research services conducted in a laboratory; scientific and technological services, namely, scientific research and analysis, in the fields of medicine, health, fitness, exercise and wellness; consulting services in the field of pharmaceutical research and development, namely, consultation and collaboration with industry and academic professionals for the identification, research and development of new manufacturing technologies in the field of pharmaceuticals | ACTIVE | — |
| 044 | Providing information in the field of medicine and health; medical services; medical assistance services; hygiene care for human beings being health care services; medical clinic services; providing medical information to patients for better lifestyle management to handle the treatment of side effects in the course of treatment of cancer, pain management, skin care, management of diabetes, management of asthma, Chronic Obstructive Pulmonary Disease (COPD) and respiratory diseases | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks owned by Glenmark Pharmaceuticals Limited
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named IGI
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 3, 2026 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Aug 3, 2026 | EXT3 | SOU EXTENSION 3 FILED | — |
| Aug 3, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 4, 2026 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 3, 2026 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Feb 3, 2026 | EXT2 | SOU EXTENSION 2 FILED | — |
| Feb 3, 2026 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 4, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Aug 4, 2025 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Aug 3, 2025 | EXT1 | SOU EXTENSION 1 FILED | — |
| Aug 3, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| May 19, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 19, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 19, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 4, 2025 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Dec 10, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 10, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 4, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 18, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 15, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 14, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 14, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Aug 26, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 26, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 1, 2024 | MDSM | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Jun 1, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 31, 2024 | NWAP | NEW APPLICATION ENTERED | — |